CalciMedica(CALC) - 2025 Q1 - Quarterly Results

Financial Performance - CalciMedica reported a net loss of $5.9 million for the first quarter of 2025, compared to a net income of $0.1 million for the same period in 2024[15]. - Total operating expenses for the first quarter of 2025 were $6.5 million, compared to $5.8 million for the same period in 2024[21]. - General and administrative expenses decreased to $2.3 million for the first quarter of 2025, down from $2.8 million in the same period of 2024[15]. Research and Development - Research and development expenses increased to $4.2 million for the three months ended March 31, 2025, up from $2.9 million in the same period of 2024, primarily due to activities related to the Phase 2 KOURAGE clinical trial[11][12]. - The Phase 2 KOURAGE trial is ongoing, with an expected enrollment of 150 patients and data anticipated around the end of 2025[4]. - CalciMedica plans to hold an end-of-Phase 2 meeting with the FDA around mid-2025 and aims to initiate a Phase 3 program in acute pancreatitis by the end of 2025[10]. - A post-hoc analysis from the Phase 2 CARDEA trial indicated a 62.7% relative reduction in mortality for patients treated with Auxora compared to placebo[5]. Financial Position - Cash, cash equivalents, and short-term investments totaled $24.6 million as of March 31, 2025, which is expected to fund operations into mid-2026[11]. - Total assets increased to $25.3 million as of March 31, 2025, compared to $19.8 million as of December 31, 2024[19]. - The company announced a credit facility providing up to $32.5 million, with an initial tranche of $10 million fully funded at close[8].